Lina Khan Is Sending a Message to the Private Equity Industry

Episode Summary

Executive Summary: The episode centers on FTC Chair Lina Khan’s antitrust agenda, especially actions against private equity roll-ups in healthcare and broader enforcement on labor markets, non-competes, and pharma consolidation. Khan argues that competition law is meant to stop anti-competitive acquisition strategies, protect workers and patients, and deter behavior before it becomes widespread, even amid political pushback and criticism that enforcement could chill investment.

Main Topics: FTC action against private equity roll-ups in healthcare (Priority: 5/5): Khan explains the FTC’s lawsuit against U.S. Anesthesia Partners and Welsh Carson as a roll-up scheme that consolidated fragmented anesthesiology markets in Texas, reduced competition, and enabled price increases. Antitrust as an old-school legal framework (Priority: 5/5): Khan rejects the idea that her approach is a novel or 'hipster' form of antitrust, arguing that the FTC is simply applying century-old statutes to modern business models and market structures. Labor markets, workers, and non-competes (Priority: 5/5): The conversation expands antitrust beyond consumer prices to labor markets, with Khan describing FTC efforts against non-compete clauses and emphasizing harms to wages, mobility, and innovation. How the FTC investigates markets (Priority: 4/5): Khan outlines the FTC’s research process: deep staff expertise, broad public comment, commission meetings, and outreach to market participants such as doctors, pharmacies, and patient advocates. Pharma consolidation and 'killer acquisitions' (Priority: 4/5): The discussion covers FTC concerns that acquisitions in pharmaceuticals can suppress competition by eliminating pipeline drugs or blocking biosimilars and generics, raising long-term prices and limiting innovation. Political pressure and deterrence (Priority: 4/5): Khan addresses criticism from Wall Street and lobbying pressure, saying pushback is expected when enforcement is effective and that early deal-stage antitrust caution is itself a sign of deterrence.

Key Arguments: Private equity roll-ups can be anti-competitive when multiple small acquisitions are analyzed in aggregate and they eliminate meaningful rivalry in a market. Healthcare deserves special scrutiny because it is essential, costly in the U.S., and consolidation can worsen access, outcomes, and mortality, not just prices. Antitrust law already protects workers and competition in labor markets; this is not a new theory but a faithful application of existing law. Non-compete clauses can depress wages, limit worker mobility, and reduce innovation even for workers not directly subject to the clause. FTC enforcement should consider not only end consumers but also patients, workers, and other affected sides of a market. Deterrence matters: if dealmakers now discuss antitrust risk earlier, that indicates enforcement is changing behavior before lawsuits are filed. Concerns that stricter antitrust will choke off investment in innovation are not decisive; the FTC believes maintaining competitive entry and exit opportunities can better support innovation over time.

Data Points: Length of Stock Movers reports: 5 minutes or less - Bloomberg promo introducing short audio reports U.S. health spending: around a fifth of GDP - Khan describing the scale of U.S. healthcare costs U.S. healthcare cost relative to OECD average: close to twice as much - Khan comparing U.S. spending to other OECD countries Non-compete wage impact: $300 billion a year - FTC-referenced estimate of wages depressed by non-compete clauses FTC suit timeline: first roll-up case in several decades - Khan characterizing the U.S. Anesthesia Partners/Walsh Carson case Horizon drugs treatment cost: $400,000 to $600,000 for a six-month treatment - Khan discussing expensive specialty drugs in the Amgen-Horizon context FTC merger guidelines comments: thousands and thousands - Khan noting public input on draft merger guidelines Drug/healthcare specialties in review: PBMs, hospital markets, pharma markets, nursing homes, emergency medicine - Examples of sectors discussed as targets of FTC scrutiny U.S. Anesthesia Partners case geography: Texas - The FTC complaint focused on anesthesiology markets in Texas Chicken market structure: millions of consumers, thousands of farmers, very small number of processing companies - Khan describing consolidation in poultry markets

Pivotal Quotes: "This is the first roll up case that the FTC has brought in several decades." — Lina Khan: Explaining why the U.S. Anesthesia Partners case is significant beyond its specific facts "The best antitrust is no antitrust" — Lina Khan: Describing and rejecting the 1970s-80s hands-off philosophy that she says the agencies are revisiting "The antitrust laws protect everybody. They protect patients and consumers, but they're also supposed to protect workers." — Lina Khan: Framing the FTC’s broader view of competition law across product and labor markets

Implications: The episode signals a durable shift toward more aggressive antitrust enforcement in healthcare, labor, and pharma. For listeners, it suggests more scrutiny of PE roll-ups, non-competes, and merger activity—and potentially better prices, wages, and access if courts uphold the FTC’s approach.